Intellectual Product
Novartis Fails to Block MSN’s Entresto Generic Launch
Novartis, Entresto, MSN Pharmaceuticals, generic drugs, patent infringement, FDA approval
Amgen Boosts Full-Year Sales Forecast Following Horizon-Driven Revenue Surge
Amgen, full-year sales forecast, Horizon acquisition, revenue growth, pharmaceutical industry
Madrigal’s MASH Drug Rezdiffra Surpasses Q2 Sales Estimates
Madrigal Pharmaceuticals, Rezdiffra, MASH drug, Q2 earnings, sales estimates, FDA approval, commercial launch, NASH treatment
University of Pennsylvania Sues BioNTech Over Unpaid COVID-19 Vaccine Royalties
University of Pennsylvania, BioNTech, COVID-19 vaccine, patent royalties, lawsuit
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations
Novartis Sues FDA Over Approval of Entresto Generic After Petition Rejection
Novartis, FDA, Entresto, generic drug, lawsuit, patent exclusivity, heart failure medication
Sanofi Sues Sarepta Over US Patents for Gene Therapy Treatments
Sanofi, Sarepta, Gene Therapy, Patents, Elevidys, Duchenne Muscular Dystrophy
FDA Criticizes Brittany Mahomes’ Paid Instagram Post for Kaléo’s Auvi-Q
FDA, Brittany Mahomes, Kaléo, Auvi-Q, misleading advertisement, social media regulation, pharmaceutical marketing
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast
PBM Executives Avoid Tough Questions in House Committee Hearing
PBM executives, House committee hearing, pharmacy benefit managers, CVS Caremark, Express Scripts, Optum Rx